Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults

- Advertisement -


Merck MRK,
-0.63%
and partner Ridgeback Biotherapeutics said their COVID-19 antiviral molanupiravir reduced the risk of hospitalization or death in at-risk adults with mild to moderate COVID-19 by 9.7% in the latest update of data from their study. up to 9.7%. move out. This equates to an absolute risk reduction of 3.0% and a relative risk reduction of 30%. “Nine deaths have been reported in the placebo group and one death in the mollupiravir group,” the companies said in a joint statement. “The adverse event profile for molnupiravir remained consistent with the profile reported in the planned interim analysis.” The companies have shared this latest data with the Food and Drug Administration, which is currently reviewing the data for potential emergency use authorization for the treatment. Antivirals are expected to be a game changer in the pandemic because they can be easily taken at home, unlike existing treatments, which must be administered either by infusion or subcutaneously in a clinical setting. Merck shares were down 2.8% premarket.

- Advertisement -

,

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox